CL2019003288A1 - Una combinación farmacéutica para el tratamiento de un cáncer. - Google Patents

Una combinación farmacéutica para el tratamiento de un cáncer.

Info

Publication number
CL2019003288A1
CL2019003288A1 CL2019003288A CL2019003288A CL2019003288A1 CL 2019003288 A1 CL2019003288 A1 CL 2019003288A1 CL 2019003288 A CL2019003288 A CL 2019003288A CL 2019003288 A CL2019003288 A CL 2019003288A CL 2019003288 A1 CL2019003288 A1 CL 2019003288A1
Authority
CL
Chile
Prior art keywords
treatment
pharmaceutical combination
cancer
simultaneous
separate
Prior art date
Application number
CL2019003288A
Other languages
English (en)
Inventor
Garcia Carles Domènech
Alfón Coriat José Alberto
Montoyo Héctor Pérez
Segura Ginard Miguel Francisco
Lizcano De Vega Jose Miguel
Original Assignee
Ability Pharmaceuticals S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ability Pharmaceuticals S L filed Critical Ability Pharmaceuticals S L
Publication of CL2019003288A1 publication Critical patent/CL2019003288A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMBINACIÓN FARMACÉUTICA QUE COMPRENDE (A): UN ÁCIDO GRASO POLIINSATURADO Y (B): UN COMPUESTO DE AGENTE QUIMIOTERAPÉUTICO PARA EL USO SIMULTÁNEO, SEPARADO O SECUENCIAL EN EL TRATAMIENTO DE UN CÁNCER EN UN PACIENTE HUMANO.
CL2019003288A 2017-05-16 2019-11-15 Una combinación farmacéutica para el tratamiento de un cáncer. CL2019003288A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17382282 2017-05-16

Publications (1)

Publication Number Publication Date
CL2019003288A1 true CL2019003288A1 (es) 2020-05-08

Family

ID=58765794

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003288A CL2019003288A1 (es) 2017-05-16 2019-11-15 Una combinación farmacéutica para el tratamiento de un cáncer.

Country Status (15)

Country Link
US (2) US11260042B2 (es)
EP (2) EP4234035A3 (es)
JP (1) JP7208650B2 (es)
KR (1) KR102569052B1 (es)
CN (1) CN110636842A (es)
AU (1) AU2018269462B2 (es)
BR (1) BR112019023944A2 (es)
CA (1) CA3063625A1 (es)
CL (1) CL2019003288A1 (es)
ES (1) ES2955524T3 (es)
HU (1) HUE063275T2 (es)
MX (1) MX2019013683A (es)
PL (1) PL3624786T3 (es)
WO (1) WO2018210830A1 (es)
ZA (1) ZA201907286B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103170A1 (en) 2020-02-10 2022-12-21 Ability Pharmaceuticals S.L. A pharmaceutical combination for the treatment of a cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258816A (ja) * 1987-04-16 1988-10-26 Nippon Oil & Fats Co Ltd 抗癌剤組成物
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
GB9618420D0 (en) * 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
JP2003508487A (ja) * 1999-09-09 2003-03-04 イーエフエイ サイエンシーズ エルエルシー． 癌を含む細胞増殖障害を処置するための方法
ES2345241B1 (es) 2009-03-16 2011-09-08 Lipopharma Therapeutics Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos.
ES2401629B1 (es) * 2011-10-07 2014-03-04 Universitat De Les Illes Balears Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos.

Also Published As

Publication number Publication date
WO2018210830A1 (en) 2018-11-22
CN110636842A (zh) 2019-12-31
PL3624786T3 (pl) 2023-10-30
EP3624786B1 (en) 2023-07-05
EP4234035A3 (en) 2023-11-15
EP3624786C0 (en) 2023-07-05
JP7208650B2 (ja) 2023-01-19
US11260042B2 (en) 2022-03-01
KR20200005573A (ko) 2020-01-15
AU2018269462A1 (en) 2019-11-28
US20210154166A1 (en) 2021-05-27
EP3624786A1 (en) 2020-03-25
JP2020520385A (ja) 2020-07-09
MX2019013683A (es) 2020-01-15
US20220257554A1 (en) 2022-08-18
ES2955524T3 (es) 2023-12-04
ZA201907286B (en) 2021-01-27
CA3063625A1 (en) 2018-11-22
RU2019135507A3 (es) 2021-09-03
HUE063275T2 (hu) 2024-01-28
BR112019023944A2 (pt) 2020-06-09
EP4234035A2 (en) 2023-08-30
RU2019135507A (ru) 2021-06-16
KR102569052B1 (ko) 2023-08-22
AU2018269462B2 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018000223A1 (es) Combinación de antagonista de pd-1 con un inhibidor de egfr
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CO2017001994A2 (es) Compuestos activos hacia bromodominios
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
GT201700179A (es) Formulaciones en polvo nasal para el tratamiento de hipoglicemia
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CO2017005968A2 (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.